Anzeige
Mehr »
Login
Sonntag, 23.02.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
851 % Rendite in 30 Tagen: Die KI-Aktie, die seit der Integration von Deepseek R1 Wellen schlägt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
331 Leser
Artikel bewerten:
(1)

Combining best-in-class AI-powered Technologies for Musculoskeletal (MSK) Imaging Workflows - ImageBiopsy Lab and Radiobotics sign Collaboration Agreement

Finanznachrichten News

VIENNA, Sept. 22, 2023 /PRNewswire/ -- ImageBiopsy Lab (Vienna, Austria) and Radiobotics (Copenhagen, Denmark) have teamed up to advance the use of Artificial-Intelligence (AI) supported disease diagnostics for musculoskeletal (MSK), orthopaedic, and trauma use-cases in the DACH region.

Combining best-in-class AI-powered Technologies for Musculoskeletal (MSK) Imaging Workflows

Globally, musculoskeletal conditions affect a larger population than circulatory or respiratory disorders. Despite this, diagnostic methods often remain rooted in outdated practices, relying on manual interpretation of X-rays and MRI images. These subjective and time-intensive techniques lack standardisation and depend on practitioner expertise.

Despite a growing number of MSK-specific solutions, users lack a holistic answer for diverse diagnostic needs. With their collaboration ImageBiopsy Lab and Radiobotics (both with MDR and FDA clearances) will merge their expertise and provide a single, comprehensive solution for MSK imaging, encompassing measurement, scoring, and fracture detection workflow.

Dr. Richard Ljuhar, CEO and Co-Founder of ImageBiopsy Lab, explains, "Before even considering the use of AI, it's crucial to grasp physicians' diagnostic workflow and needs. For this purpose we've closely collaborated with leading MSK radiologists, orthopaedics, and traumatologists over the past years. We're committed to revolutionizing the entire MSK diagnostic value chain for practitioners, patients, and healthcare systems.

We see Radiobotics as the logical partner to offer best in class solutions for MSK conditions diagnostics, from measurements and scoring to fracture detection. Our collaboration marks the next AI-powered workflow integration phase.

Mads Jarner, CEO and Co-founder of Radiobotics, notes, "As MSK AI solutions gain traction in clinical workflows, providing clinics with integrated and comprehensive options becomes vital. We're thrilled to collaborate with ImageBiopsy Lab to facilitate access to our market-leading solutions. Leveraging ImageBiopsy Lab's expertise and network in German-speaking regions, we're excited to introduce our RBfracture fracture detection solution in this area initially, with potential expansion to other regions.

About

ImageBiopsy Lab and Radiobotics are both considered pioneers in the field of deep learning technology applied to musculoskeletal imaging analysis. Over the course of their development, the two award-winning companies have progressively specialised in distinct areas. ImageBiopsy Lab excels with a comprehensive portfolio of automated measurement solutions, while Radiobotics leads in fracture detection. By joining forces, they aim to cover the complete spectrum of radiologists' and orthopaedics' needs.

For media inquiries: Annalisa Blaha, marketing@imagebiopsy.com, +43 1905 12061104

Photo - https://mma.prnewswire.com/media/2216088/ImageBiopsy_Lab.jpg
Logo - https://mma.prnewswire.com/media/2129308/4282896/ImageBiopsy_lab_Logo.jpg

ImageBiopsy Lab Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/combining-best-in-class-ai-powered-technologies-for-musculoskeletal-msk-imaging-workflows---imagebiopsy-lab-and-radiobotics-sign-collaboration-agreement-301935481.html

© 2023 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.